INTEGRATIVE ANALYSIS OF PHARMACOTHERAPY, BIOMARKERS, AND BIOMEDICAL MECHANISMS IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES MELLITUS

Authors

Keywords:

type 2 diabetes mellitus, chronic kidney disease, diabetic kidney disease, biomarkers, pharmacotherapy, SGLT2 inhibitors, NGAL, KIM-1, oxidative stress, proteomics, metabolomics.

Abstract

This article provides an integrative analysis of the mechanisms underlying chronic kidney disease associated with type 2 diabetes mellitus, contemporary pharmacotherapeutic approaches, and the diagnostic and prognostic significance of emerging biomarkers based on recent scientific evidence. Particular attention is given to the pathogenetic contribution of hyperglycemia, oxidative stress, chronic inflammation, endothelial dysfunction, glomerular and tubulointerstitial injury, and fibrosis to the development and progression of diabetic kidney disease. In addition to conventional indicators such as albuminuria and estimated glomerular filtration rate, the potential clinical value of NGAL, KIM-1, cystatin C, and biomarkers of inflammation and oxidative stress for early detection and assessment of disease progression is discussed. Current pharmacotherapeutic strategies involving SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and agents targeting the renin–angiotensin–aldosterone system are evaluated with particular emphasis on their nephroprotective effects. The prospects of proteomics, metabolomics, and multi-omics technologies for identifying novel biomarkers and therapeutic targets are also considered. The available evidence suggests that integrating pharmacological, analytical, and biomedical approaches may improve early diagnosis, individualized risk stratification, and personalized treatment strategies for chronic kidney disease associated with type 2 diabetes mellitus.

References

1.Lovshin JA. Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice. Nephrol Dial Transplant. 2026 Aug 18. doi:10.1093/ndt/gfag136.

2.Efiong EE, Maedler K, Effa E, Osuagwu UL, Peters E, Ikebiuro JO, et al. Decoding diabetic kidney disease: a comprehensive review of interconnected pathways, molecular mediators, and therapeutic insights. Diabetol Metab Syndr. 2025;17(1):192. doi:10.1186/s13098-025-01726-4.

3.Shetty S, Suvarna R, Awasthi A, Bhojaraja MV, Pappachan JM. Emerging biomarkers and innovative therapeutic strategies in diabetic kidney disease: a pathway to precision medicine. Diagnostics (Basel). 2025;15(8):973. doi:10.3390/diagnostics15080973.

4.Rroji M, Bob F, Lo Cicero L, Figurek A, Spasovski G. Biomarkers in diabetic kidney disease: early detection, prognostic assessment, and integration with multi-omics signatures. Life (Basel). 2026;16(7):1164. doi:10.3390/life16071164.

5.Zhang H, Chen J, Wang N, Chen W, Xu Y, Gui D. Advancements in pharmacotherapy for diabetic kidney disease: a systematic review. Diabetes Metab Res Rev. 2025;41(6). doi:10.1002/dmrr.70077.

6.Joumaa JP, Raffoul A, Sarkis C, Chatrieh E. Mechanisms, biomarkers, and treatment approaches for diabetic kidney disease: current insights and future perspectives. J Clin Med. 2025;14(3):727. doi:10.3390/jcm14030727.

7.Zhang H, Wang K, Zhao H, Qin B, Cai X, Wu M, et al. Diabetic kidney disease: from pathogenesis to multimodal therapy—current evidence and future directions. Front Med (Lausanne). 2025;12:1631053. doi:10.3389/fmed.2025.1631053.

8.Ma L, Liu D, Yu Y, Li Z, Wang Q. Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy. Front Immunol. 2025;16:1587806. doi:10.3389/fimmu.2025.1587806.

9.Meng J, Zhang W, Wang H, He Z, Zhang Z. Progression of early diagnostic markers for diabetic kidney disease: from single-indicator detection to multi-omics integration modeling. Curr Res Physiol. 2026;9:100190. doi:10.1016/j.crphys.2026.100190.

10.Van Roy N, Speeckaert MM. The potential use of targeted proteomics and metabolomics for the identification and monitoring of diabetic kidney disease. J Pers Med. 2024;14(10):1054. doi:10.3390/jpm14101054.

11.Hill C, McKnight AJ, Smyth LJ. Integrated multiomic analyses: an approach to improve understanding of diabetic kidney disease. Diabet Med. 2025;42(2). doi:10.1111/dme.15447.

12.Guo J, Wei M, Zhang W, Jiang Y, Li A, Wang C, et al. Clinical efficacy and safety of sodium-glucose cotransporter protein-2 inhibitor, glucagon-like peptide-1 receptor agonist, and finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. Front Pharmacol. 2025;16:1517272. doi:10.3389/fphar.2025.1517272.

13.Martinez Leon V, Hilburg R, Susztak K. Mechanisms of diabetic kidney disease and established and emerging treatments. Nat Rev Endocrinol. 2026;22(1):21–35. doi:10.1038/s41574-025-01171-3.

14.Verma A, Upadhyay A. Diabetic kidney disease, biomarkers, and finerenone. Diabetes Obes Metab. 2026;28(4):2582–2593. doi:10.1111/dom.70464.

Published

2026-09-18